← Back to Search

Radiation Therapy

SUPR vs 3D Radiotherapy for Bone Metastases from Cancer

N/A
Recruiting
Led By Rob Olson, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient must be prescribed a 5-HT3 receptor antagonist (e.g. Ondansetron) as antiemetic prophylaxis prior to RT start
Clinical diagnosis of cancer with bone metastases (biopsy not required)
Must not have
Serious medical co-morbidities precluding radiotherapy
Clinical evidence of spinal cord compression
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 weeks, and 4 weeks post treatment
Awards & highlights

Summary

This trial is testing whether a different type of radiation therapy can help control nausea and vomiting caused by radiation therapy, with the goal of improving quality of life.

Who is the study for?
This trial is for adults with cancer who have bone metastases and are receiving palliative radiotherapy. They must be taking a specific anti-nausea medication, have no more than three radiation fields needing treatment, and not be pregnant or breastfeeding. Patients should be able to complete quality of life questionnaires and follow-up visits.
What is being tested?
The SUPR-3D study compares the effects on quality of life between standard palliative radiotherapy (SUPR) and Volumetric Modulated Arc Therapy (VMAT). It focuses on controlling nausea/vomiting from radiation and will also evaluate pain response, although no difference is expected in pain control.
What are the potential side effects?
Potential side effects may include Radiation Induced Nausea and Vomiting (RINV), which the trial aims to manage. Other common side effects from radiotherapy can range from skin reactions at the treatment site to fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am prescribed medication to prevent vomiting before starting radiation therapy.
Select...
My cancer has spread to my bones.
Select...
I am receiving targeted radiation for bone metastases in my mid to lower spine or pelvis.
Select...
I can care for myself but may not be able to do heavy physical work.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have serious health issues that prevent me from receiving radiation therapy.
Select...
I have signs of pressure on my spinal cord.
Select...
My spinal cord has been exposed to over 30 Gy of radiation.
Select...
I have a single plasma cell tumor.
Select...
More than two of my organs need special care during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 weeks, and 4 weeks post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 weeks, and 4 weeks post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient Reported Quality of life related to Radiation Induced Nausea and Vomiting (RINV)
Secondary study objectives
Control of RINV Radiation Induced Nausea and Vomiting (RINV)
Economic Analysis
Patient Reported Fatigue, Nausea, Vomiting
+3 more

Trial Design

2Treatment groups
Active Control
Group I: VMAT rapid (Arm 2)Active Control1 Intervention
Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows: * If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion * If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion * If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ
Group II: SUPR (Arm 1)Active Control1 Intervention
Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard. Minimum of kV image matching on unit daily.

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
172 Previous Clinical Trials
90,354 Total Patients Enrolled
Rob Olson, MDPrincipal InvestigatorBritish Columbia Cancer Agency

Media Library

SUPR (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03694015 — N/A
Cancer Research Study Groups: VMAT rapid (Arm 2), SUPR (Arm 1)
Cancer Clinical Trial 2023: SUPR Highlights & Side Effects. Trial Name: NCT03694015 — N/A
SUPR (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03694015 — N/A
~34 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top